Start your intake How Tirzepatide and Semaglutide Work Differently Tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it stimulates two separate hormonal pathways in your body
This can help individuals eat less, leading to an average weight loss of 15% when combined with diet and exercise
Consideration should be made to stop semaglutide if less than 5% of the initial weight has been lost after 6 months of treatment
2024;7:e246221
However, on GLP-1 therapy, appetite is already significantly reduced [4] many patients naturally eat well below their TDEE without counting calories
Primary Care Update By Mark Ebell Episode 211: semaglutide for AUD, preventing post-vax syncope, PCR panel for RTI, fluvoxamine for long-COVID Join primary care professors Mark Ebell, Kate Rowland, Gary Ferenchick and Henry Barry as they discuss 4 new studies: semaglutide for alcohol use disorder, a vibrating cool pack to prevent post vaccination syncope, PCR for 23 respiratory pathogens in primary care to reduce antibiotic use, and fluvoxamine for Long-COVID Fatigue